BTK and B-cell chronic lymphocytic leukemia: Should CLL cells differentially downregulate the use of signaling axes which depend on BKT or PI3K, it is plausible that these patients may be resistant to the BTK and PI3K protein kinase inhibitors ibrutinib or idelalisib.